Ken Maes
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Cancer Research top 5%
- MicroRNA in disease regulation
Papers in
-
- Histone Deacetylase Inhibitors Research 12
- Protein Degradation and Inhibitors 11
- Ubiquitin and proteasome pathways 8
- Epigenetics and DNA Methylation 8
- Extracellular vesicles in disease 6
- Hematology 27
- Multiple Myeloma Research and Treatments 24
- Co-authors
- Karin Vanderkerken (44 shared papers)Elke De Bruyne (44 shared papers)Eline Menu (41 shared papers)Kim De Veirman (30 shared papers)Els Van Valckenborgh (20 shared papers)Nathan De Beule (10 shared papers)Jinheng Wang (3 shared papers)Rik Schots (8 shared papers)
In The Last Decade
Ken Maes
50 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 83
- Hematology 618
- Cancer Research 320
- Oncology 360
- Molecular Biology 957
- Immunology 254
Countries citing papers authored by Ken Maes
This map shows the geographic impact of Ken Maes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Maes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Maes more than expected).
Fields of papers citing papers by Ken Maes
This network shows the impact of papers produced by Ken Maes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Maes. The network helps show where Ken Maes may publish in the future.
Co-authors
The 25 scholars most cited alongside Ken Maes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 52 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 139 | |
| 2 | 2018 | 127 | |
| 3 | 2016 | 114 | |
| 4 | 2010 | 113 | |
| 5 | 2015 | 65 | |
| 6 | 2016 | 57 | |
| 7 | 2016 | 56 | |
| 8 | 2018 | 55 | |
| 9 | 2014 | 51 | |
| 10 | 2018 | 49 | |
| 11 | 2019 | 48 | |
| 12 | 2020 | 48 | |
| 13 | 2016 | 46 | |
| 14 | 2018 | 45 | |
| 15 | 2017 | 44 | |
| 16 | 2013 | 43 | |
| 17 | 2017 | 43 | |
| 18 | 2015 | 41 | |
| 19 | 2018 | 32 | |
| 20 | 2017 | 30 |
About Ken Maes
Ken Maes is a scholar working on Molecular Biology, Hematology, Oncology, Immunology and Cell Biology, having authored 52 papers that have together received 1.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (24 papers), Histone Deacetylase Inhibitors Research (12 papers), Protein Degradation and Inhibitors (11 papers), Ubiquitin and proteasome pathways (8 papers), Epigenetics and DNA Methylation (8 papers), Immune cells in cancer (7 papers), Extracellular vesicles in disease (6 papers) and Microtubule and mitosis dynamics (4 papers). The work is most often cited by research in Hematology (618 citations), Cancer Research (320 citations), Oncology (360 citations), Molecular Biology (957 citations) and Immunology (254 citations). Ken Maes has collaborated with scholars based in Belgium, France and Germany. Frequent co-authors include Karin Vanderkerken, Elke De Bruyne, Eline Menu, Kim De Veirman, Els Van Valckenborgh, Nathan De Beule, Jinheng Wang, Rik Schots, Sylvia Faict and Hendrik De Raeve. Their work appears in journals such as Oncotarget, Blood, Frontiers in Immunology, Cancers and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.